HR-positive Breast Cancer

Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer

Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer

By

In this open label phase 2 BOLERO-4 study, researchers evaluated the effect of everolimus plus endocrine therapy on progression-free survival.

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

By

Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.

Oncotype DX Recurrence Score a Potential Marker of Hereditary Breast Cancer

Oncotype DX Recurrence Score a Potential Marker of Hereditary Breast Cancer

By

Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.

Letrozole Not Superior to Anastrazole for HR+, Node+ Early Breast Cancer

Letrozole Not Superior to Anastrazole for HR+, Node+ Early Breast Cancer

By

Letrozole was not superior to anastrazole with respect to efficacy or safety in postmenopausal women with HR-positive, node-positive early breast cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs